US FDA’s Comirnaty Review By The Numbers
Executive Summary
A timeline of the review and development of the first COVID-19 vaccine to win BLA approval.
You may also be interested in...
Moderna’s Pediatric COVID Vaccine Packaging Spurs Confusion Concerns From CDC Panel
Discrete packaging for authorized dose in 6-11 year-olds is not yet available, so vaccination providers have to use product from a vial labeled for ‘booster doses only’ in adults. ACIP members unanimously endorse use of the mRNA vaccine in individuals ages 6-17 years but urge manufacturers to move away from relying on color to differentiate formulations.
Acadia’s Nuplazid Needs Another Study For Alzheimer’s Psychosis, US FDA Panel Says
Advisory committee members cited a litany of shortfalls with efficacy data from two existing studies and say a new Phase III trial is needed in a large, ethnically and racially diverse population of Alzheimer’s disease psychosis patients.
Acadia’s Nuplazid: US FDA Panel Will Focus On Efficacy For Alzheimer’s Disease Psychosis
Agency questions clinical significance of change in primary efficacy endpoint measured in one study and raises doubts about numerous exploratory analyses for a second study aimed at explaining why Alzheimer’s patient subgroup appeared to derive less benefit than other types of dementia patients.